Navigation Links
New approach to treating human brain cancer could lead to improved outcomes
Date:9/25/2013

f the SHH pathway that regulate cell growth during normal development. The mutations cause cell signaling to go awry, triggering the creation of cancer cells that grow uncontrollably and establish tumors. SHH-associated tumors account for 25 percent of all human cases of medulloblastoma, and the SHH pathway has been implicated in other tumor types such as lung, breast, prostate, and skin cancer.

"Our increased understanding of SHH-associated tumors has recently led to the development of drugs that specifically inhibit the SHH pathway. Early studies in humans with these new drugs have offered some hope for patients, but many do not respond and most patients who do respond develop resistance to the drug. For this reason, it is essential to develop alternative, or additional, therapies that are more effective than current treatment options," Wechsler-Reya said.

The team's first set of experiments used a mouse model for SHH-dependent medulloblastoma. In-vitro studies of mouse tumor cells showed that cell-cycle inhibitors caused tumor cell death. In vivo, mice that were treated with the inhibitor had smaller tumors that weighed less compared to mice that were not treated, essentially halting the progression of the tumor.

The second set of experiments used human SHH-dependent medulloblastoma cells. When the researchers treated these human tumor cells with cell-cycle inhibitors, they also observed a significant reduction in tumor growth and progression.

Finally, when the scientists combined SHH inhibitors with cell-cycle inhibitors, they found that the combination worked together to produce results that were greater than either inhibitor alone.

"These results strongly support an approach to treatment that combines SHH inhibitors with cell-cycle inhibitors to treat medulloblastoma. Our hope is that the combination of these inhibitors will prevent tumor progression and drug resistance, and improve the overall effectiveness of curr
'/>"/>

Contact: Susan Gammon, Ph.D.
sgammon@sanfordburnham.org
310-610-3808
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. A new approach to early diagnosis of influenza
2. Novel approach to gene regulation can activate multiple genes simultaneously
3. Mechanism offers promising new approach for harnessing the immune system to fight cancer
4. Study highlights possible new approach to prostate cancer treatment
5. Notre Dame researchers develop system that uses a big data approach to personalized healthcare
6. New approach to protecting prion protein from altering shape
7. New data support community-wide approach to addressing child obesity
8. A Future-Proof Approach to Intelligent Buildings
9. New chemical approach to treat Alzheimers
10. Agencies should use common approach to evaluate risks pesticides pose to endangered species
11. Novel therapeutic approaches to cure chronic HBV infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... Warming oceans are causing marine species to change breeding ... the broader marine landscape, according to a new global ... National Centre for Ecological Analysis and Synthesis in California, ... distribution of species and phenology the timing of ...
... researchers from Philadelphia and Norway has determined the structure of ... proteins and is made at elevated levels in numerous forms ... Biology , led by researchers at The Wistar Institute, depicts ... complex called NatA. Their findings, they believe, will allow ...
... cells into liver cells and inducing successful infection, researchers from ... for the first time that the hepatitis C virus (HCV) ... journal Gastroenterology . The new findings may lead to ... developing treatments and vaccines for this disease, which impacts more ...
Cached Biology News:Global investigation reveals true scale of ocean warming 2Wistar scientists decipher structure of NatA, an enzyme complex that modifies most human proteins 2Mount Sinai researchers develop first successful laboratory model for studying hepatitis C 2
(Date:6/2/2015)... June 2, 2015 GOJO, inventors of PURELL ... to antibiotic stewardship at the White House Forum.  GOJO ... health organizations and stakeholders at the White House Forum ... slow the emergence of antibiotic-resistant bacteria, detect resistant strains, ... the spread of resistant infections. "A primary ...
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 German-based ... official United States distributor for the Moenninghoff product ... stated, “I am pleased to announce that the R.M. ... market. For our firm, founded in 1916, this is ... R.M. Hoffman is the kind of professional distributor we ...
(Date:6/1/2015)... NEW YORK , June 1, 2015 /PRNewswire/ ... medical researcher  Eliseo Oreste Salinas , MD, MSc, ... and development. Dr. Salinas, who holds ... in pharmacology, brings a record of significant accomplishments ... in psychiatry.  Dr. Salinas has played ...
(Date:6/1/2015)... CHICAGO and RARITAN, N.J. ... & Development, LLC (Janssen) announced data from the ... significant improvement in progression-free survival (PFS) with trabectedin ... with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously ... additional chemotherapy regimen. SAR3007 is the largest randomized ...
Breaking Biology Technology:GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6
... ... ... , ... , , , , ...
... of Helsinki have managed to manufacture new polymer-stabilised silver ... of silver are used in textiles, floor coatings and ... nanoparticles are not entirely known. Finnish researchers now think ... binding the nanoparticles to polymers. The research results will ...
... ... Organizations , ... Shores, California (PRWEB) February 24, 2010 -- Model N , Inc., the leader ... Authoring solution, which extends the Model N Revenue Management Suite by allowing business users ...
Cached Biology Technology:Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program 2Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program 3Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program 4The toxicity of antimicrobial silver in products can be reduced 2The toxicity of antimicrobial silver in products can be reduced 3Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 2Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 3Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 4Model N Extends its Industry-Leading Contract Management Offerings with Contract Authoring Capabilities 5
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent - EDTA, 10 L...
... gel electrophoresis into an automated, high-throughput operation ... pre-cast system is ideal for analyzing multiple ... more. Fully automated, robot-compatible, and ready to ... makes your high-throughput screening assignments as easy ...
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Biology Products: